Neurophth Therapeutics and Abogen Biosciences Announce Strategic Partnership to Develop mRNA-Based Therapies for the Treatment of Retinal Diseases

The 3rd BIO International Convention 2022 is Approaching

Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy

Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer

Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies

Qiutang Li, Neurophth CSO, Named Top 25 Women Leaders in Biotechnology 2021

Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards